JPMorgan Chase Financial Co. LLC has filed a pricing supplement for $886,000 in auto callable contingent interest notes linked to the MerQube US Large-Cap Vol Advantage Index. This filing, dated October 21, 2026, is significant as it showcases the company's ongoing efforts to innovate within the structured investment market.
The notes are designed for investors who seek contingent interest payments based on the performance of the index, which is subject to a 6.0% annual deduction. The filing emphasizes the potential for investors to receive a contingent interest payment if the index meets specified performance criteria.
Background
JPMorgan Chase Financial Co. LLC is a finance subsidiary of JPMorgan Chase & Co., incorporated in Delaware. The company operates under the Standard Industrial Classification of National Commercial Banks (SIC: 6021). Recent filings include multiple pricing supplements and related documents, reflecting active engagement in the structured investments market.
What the Filing Says
The pricing supplement outlines the terms of the notes, stating, "The notes are designed for investors who seek a Contingent Interest Payment with respect to each Review Date for which the closing level of the MerQube US Large-Cap Vol Advantage Index... is greater than or equal to 55.00% of the Initial Value." The notes are fully and unconditionally guaranteed by JPMorgan Chase & Co.
Impact
This filing may affect a range of stakeholders, including investors looking for innovative financial products, as well as competitors in the national commercial banking sector. The structured nature of these notes may attract investors who are willing to accept certain risks for potential higher returns.
What's Next
The filing does not say what happens next.
Read Next
Sunrun Inc. Amends Bylaws to Enhance Governance Practices
Bioxytran launches first two nutraceutical products
Ericsson announces share buyback program for November 2026
Ferrari announces share buyback as part of €3.5 billion program
American Express Reports Delinquency and Write-off Statistics
Novo Nordisk announces DKK 15 billion share repurchase plan










